Johnson & Johnson’s COVID-19 Vaccine Receives Health Canada Approval for the Prevention of COVID-19 in Individuals Aged ≥18 years
Shots:
- The approval was based on the P-III (ENSEMBLE) study to evaluate the COVID-19 vaccine in 43783 patients aged ≥18yrs. with COVID-19
- The results showed 85% vaccine efficacy in preventing severe disease & demonstrated protection against COVID-19 related hospitalization & death @28 days after vaccination while 40% of patients had comorbidities associated with an increased risk for progression to sev. COVID-19
- The vaccine is well suited for 2yrs. at -25°C to -15°C & 6mos. at temp. of 2 to 8°C. Additionally, J&J’s COVID-19 vaccine will utilize the AdVac vaccine platform to develop & manufacture EC approved Ebola vaccine regimens and this platform is also used for Zika, RSV, and HIV vaccines
Ref: J&J | Image: J&J
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com